Fennec Pharmaceuticals (FENC) Interest Expenses (2014 - 2026)

Fennec Pharmaceuticals (FENC) has 10 years of Interest Expenses data on file, last reported at $2.4 million in Q4 2025.

• Quarterly Interest Expenses rose 232.59% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.2 million (up 8.87% YoY) and the FY2025 annual result came in at $46.5 million, down 11.17% from the prior year.
• Interest Expenses advanced to $2.4 million in Q4 2025, from $586000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $2.4 million in Q4 2025 to a low of $4000.0 in Q1 2021.
• A 5-year average of $629250.0 and a median of $656000.0 in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2021 — Interest Expenses slumped 99.8% — and 2022, when it jumped 1350.0%.
• Tracing FENC's Interest Expenses over 5 years: stood at $62000.0 in 2021, then soared by 1100.0% to $744000.0 in 2022, then advanced by 22.98% to $915000.0 in 2023, then dropped by 21.53% to $718000.0 in 2024, then surged by 232.59% to $2.4 million in 2025.
• The last three Interest Expenses figures came in at $2.4 million (Q4 2025), $586000.0 (Q3 2025), and $594000.0 (Q2 2025), per Business Quant data.